Yüklüyor......
New therapies for von Willebrand disease
The management of von Willebrand disease (VWD) is based upon the dual correction of the primary hemostasis defect, due to the inherited deficiency of von Willebrand factor (VWF), and of the secondary defect of factor VIII coagulant activity (FVIII:C), due to the loss of binding and stabilization by...
Kaydedildi:
| Yayımlandı: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Yazar: | |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society of Hematology
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6913470/ https://ncbi.nlm.nih.gov/pubmed/31808884 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2019000368 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|